OOIR: Observatory of International Research

Papers

(The TQCC of Urologic Oncology-Seminars and Original Investigations is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Impact of paclitaxel, cisplatin, and gemcitabine as first-line chemotherapy in cisplatin-fit and -unfit patients with advanced/metastatic urothelial carcinoma	49
Editorial Board	47
National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy	45
Festschrift essay to celebrate Dr. Michael Droller	40
REAL-WORLD ANALYSES OF MACE AND MORTALITY RISK IN PATIENTS WITH PROSTATE CANCER AFTER INITIATION OF LHRH AGONISTS VS. GNRH ANTAGONIST	37
PREVALENCE OF OCCULT UROLOGIC MALIGNANCIES IN PATIENTS UNDERGOING SCREENING FOR LUNG CANCER	36
COMUTATIONAL PATTERNS IN FGFR3-ALTERED NON-MUSCLE INVASIVE BLADDER CANCER INFLUENCE RECURRENCE AND PROGRESSION	34
PREOPERATIVE RADICAL CYSTECTOMY ERAS SCREENING AND EDUCATION – PATIENT REPORTED OUTCOMES	33
APPLICATION OF THE STRATCANS CRITERIA TO THE MUSIC AS COHORT: A STEP TOWARDS RISK STRATIFIED ACTIVE SURVEILLANCE	31
“Published abstracts from the 24th Annual Meeting of the Society of Urologic Oncology”	31
DECIPHER® GENOMIC CLASSIFIER SCORE ON INITIAL BIOPSY IS ASSOCIATED WITH PROGRESSION FORM ACTIVE SURVEILLANCE TO TREATMENT IN PROSTATE CANCER	31
UTILITY OF C-REACTIVE PROTEIN LEVELS IN IMPROVING RISK STRATIFICATION IN METASTATIC RENAL CELL CARCINOMA	31
A QUALITATIVE EXPLORATION OF THE EXPERIENCE OF TRANSGENDER AND GENDER NONCONFORMING PATIENTS WITH GENITOURINARY AND GYNECOLOGIC MALIGNANCIES	30
GROWTH OF VON HIPPEL-LINDAU (VHL)-ASSOCIATED RENAL TUMORS DURING PREGNANCY	30
Genetic variations related to the prostate cancer risk: A field synopsis and revaluation by Bayesian approaches of genome-wide association studies	29
Predictors of discharge to home following major surgery for urologic malignancies: Results from the national surgical quality improvement program	28
Guideline discordant care in patients with metastatic germ cell tumors	27
Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer	27
Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for seminoma: Limitations of surgical intervention after first-line chemotherapy	26
Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens	26
Multicenter study of active surveillance for small renal masses: Real world practice pattern	25
Morbidity and mortality of multivisceral resection with radical nephrectomy for locally advanced renal cell carcinoma: An analysis of the National Surgical Quality Improvement Program (NSQIP) database	24
The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients	24
Safety and efficacy of intravesical Bacillus Calmette-Guerin instillation for superficial recurrence following bladder-sparing therapy of muscle invasive bladder cancer: A retrospective study	24
The role of enhanced recovery after surgery protocols in the development of acute kidney injury following radical cystectomy	24

Radical prostatectomy for patients with high-risk, very-high risk, or radiographic suspicion for metastatic prostate cancer: Perioperative and early oncologic results from the MUSIC statewide collabor	23
Evaluation of PD-L1 (E1L3N, 22C3) expression in venous tumor thrombus is superior to its assessment in renal tumor in predicting overall survival in renal cell carcinoma	23
NON-MUSCLE INVASIVE RECURRENCE AND MANAGEMENT DURING SURVEILLANCE IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ACHIEVE CLINICAL COMPLETE RESPONSE TO NEOADJUVANT CHEMOTHERAPY	23
Editorial Board	23
Is YouTube a good resource for patients to better understand kidney cancer?	22
Predictive factors associated with differential pathologic response to neoadjuvant chemohormonal therapy in high-risk localized prostate cancer	21
Guidelines versus real-world data in metastatic bladder cancer: A population-based study on first-line chemotherapy treatment patterns	21
Cover 2 - Masthead	21
Extracellular vesicles in renal cell carcinoma: A review of the current landscape and future directions	21
Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET in urothelial carcinoma is associated with discordant expression between primary and metastatic sites	21
Managing female sexual dysfunction	21
Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-3	21
Poor clinical outcomes and immunoevasive contexture in SIRPα+ tumor-associated macrophages enriched muscle-invasive bladder cancer patients	20
Comparing costs of renal preservation versus radical nephroureterectomy management among patients with non-metastatic upper tract urothelial carcinoma	20
Methodological considerations for systematic review and meta-analysis of Xpert bladder cancer monitor	20
Radical prostatectomy readmissions: Causes, risk factors, national rates, & costs	19
The centralization of bladder cancer care and its implications for patient travel distance	19
Comparing the prognostic models to predict oncologic outcomes in patients with renal cell carcinoma: is AUC close enough to clinical practice?	19
Carbonic anhydrase 10 functions as a tumor suppressor in renal cell carcinoma and its methylation is a risk factor for survival outcome	19
Predictive value of renal tumor contour irregularity score in pathological T3a upstaging of clinical T1 renal cell carcinoma: A multi-institutional study	19
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02	19
Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients	18
Salvage local treatment for recurrent prostate cancer after focal therapy: A systematic review and meta-analysis	18
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma	18
Impact of the controlling nutritional status (CONUT) score on perioperative morbidity and oncological outcomes in patients with bladder cancer treated with radical cystectomy	18
Exploring prostate-specific antigen (PSA) Testing rates and screening disparities in the all of us dataset	18
PSA kinetics and predictors of PSA response in metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors	18
FEASIBILITY AND OUTCOMES OF INTERVENTIONS TO REDUCE CYSTOSCOPY DISCOMFORT: A QUALITY IMPROVEMENT PILOT	17
RETROPERITONEAL NODAL DISTRIBUTION OF METASTATIC SEMINOMA: A CLINICAL MAPPING STUDY	17
CHEST CT SHOULD REPLACE CHEST X-RAYS TO EVALUATE FOR THORACIC RENAL CELL CARCINOMA METASTASES	17
DEFINING THE IMPACT OF PERSONAL AND FAMILY HISTORY OF LYNCH-SYNDROME ASSOCIATED CANCERS ON CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA	17
MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION (TULSA) OF LOCALIZED PROSTATE CANCER: SINGLE INSTITUTION EXPERIENCE OF TREATMENT EFFICACY	17
TUMOROID AND GENOMIC MODELING OF LOW GRADE INTERMEDIATE RISK BLADDER CANCER TO PREDICT INTRAVESICAL CHEMOTHERAPY RESPONSE	17
PSYCHOLOGICAL RESILIENCE AND DISTRESS AMONG RADICAL CYSTECTOMY PATIENTS: A SYMPTOM DISTRESS SCALE SURVEY ANALYSIS	17
INTENSIFIED MRI-BASED PROSTATE CANCER SCREENING IN GERMLINE CARRIERS OF RARE PATHOGENIC VARIANTS: INTERIM RESULTS FROM THE INITIAL SCREENING ROUND OF THE PROGRESS STUDY	17
IMPACT OF NODAL DISEASE IN NON-CLEAR CELL RENAL CELL CARCINOMA AND THE ROLE OF SALVAGE LYMPH NODE RESECTION	16
EDARADD silencing suppresses the proliferation and migration of bladder cancer cells	16
Multimodality treatment of penile cancer: Part 2	16
COMPARING WHITE LIGHT VERSUS BLUE LIGHT CYSTOSCOPY RECURRENCE OUTCOMES AMONG NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS IN AN EQUAL ACCESS SETTING: A PROPENSITY SCORED MATCHED ANALYSIS	16
Chronic kidney disease and radical cystectomy for bladder cancer: perioperative and oncologic outcomes in 1,214 patients	16
UTILIZING LOW-PASS WHOLE GENOME SEQUENCING OF URINARY-TUMOR DNA TO IDENTIFY MINIMAL RESIDUAL DISEASE PRIOR TO REPEAT TRANSURETHRAL RESECTION OF BLADDER TUMOR	16
Radiation therapy in the management of the inguinal region in penile cancer: What's the evidence?	16
Number of cores needed to diagnose prostate cancer during MRI targeted biopsy decreases after the learning curve	16
Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma	15
Tumors masquerading as type 2 papillary renal cell carcinoma: pathologists’ ever-expanding differential diagnosis for a heterogeneous group of entities	15
The impact of bladder cuff excision on outcomes after nephroureterectomy for upper tract urothelial carcinoma: An analysis of the ROBUUST 2.0 registry	15
Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma	15
Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer	15
Molecular mechanism of microRNAs, long noncoding RNAs, and circular RNAs regulating lymphatic metastasis of bladder cancer	15
Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicity	14

IMMEDIATE LYMPHATIC RECONSTRUCTION WITH LYMPHATICOVENOUS BYPASS CREATION AFTER BILATERAL INGUINAL LYMPH NODE DISSECTION FOR PENILE CANCER: A CASE SERIES	14
Corrigendum to: Mechanistic target of rapamycin (mTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy	14
Novel nomograms to predict muscle invasion and lymph node metastasis in upper tract urothelial carcinoma	14
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank	14
CLINICAL PROGRESSION OF PROSTATE CANCER FROM ACTIVE SURVEILLANCE IS PREDICTED BY DECIPHER® GENOMIC CLASSIFIER SCORE ON INDEX BIOPSY INDEPENDENT FROM RISK ASSESSMENT BY MRI CHARACTERISTICS	14
Assessing the sex-based enrollment gap in urologic oncology clinical trials	14
AUTOMATED NEPHROMETRY SCORES THROUGH DIRECT PREDICTION OF EACH COMPONENT	14
A comparison of outcomes between transperitoneal and retroperitoneal robotic assisted partial nephrectomy in patients with completely endophytic kidney tumors	13
Conditional survival of stage III non-seminoma testis cancer patients	13
Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor	13
A polygenic risk score is associated with risk of bladder cancer and earlier age of diagnosis, independent of lifestyle factors	13
Pathology focused review of morphologic subtypes and molecular variants of urothelial carcinoma with an emphasis on clinical/treatment relevance	13
Multivariate analysis of the parameters affecting the choice of surgical treatment for patients with localized renal cell carcinoma (RCC)	13
Prospective validation of the Kaiser Permanente prostate cancer risk calculator in a contemporary, racially diverse, referral population	13
Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: A single centre, prosp	13
Impact of the time elapsed between prostate biopsy and surgery on the accuracy of nomograms predicting lymph node invasion in patients with clinically localized prostate cancer	13
Healthcare costs and resource utilization associated with renal cell carcinoma among older Americans: A longitudinal case-control study using the SEER-Medicare data	13
Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non–muscle invasive bladder cancer	13
Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis	13
Prospective validation of clino-radio-pathological risk scoring system (CRiSS) for prediction of inguinal lymph-nodes metastasis in squamous cell carcinoma of penis	13
FACTORS ASSOCIATED WITH PROSTATE CANCER SCREENING AMONG HISPANIC MEN: RESULTS FROM HISPANIC COMMUNITY HEALTH STUDY/STUDY OF LATINOS (HCHS/SOL)	12
Morbidity and mortality of salvage radical prostatectomy for prostate cancer: An analysis of the National surgical quality improvement program targeted prostatectomy database	12
Table of Contents	12
Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma	12
Characteristics Contributing to Survival Differences Between Black and White Patients Following Cystectomy	12
Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT)	12
How to manage patients with suspected upper tract urothelial carcinoma in the pandemic of COVID-19?	12
Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapy	12
Pathologic and Short-Term Oncologic Outcomes of Prostate Cancer Patients Following Transvesical Robot-Assisted Radical Prostatectomy	12
Development of a specific supportive care needs scale for radical cystectomy patients and its reliability and validity test	12
Cover 2 - Masthead	12
Comparison of microwave ablation and partial nephrectomy for T1a small renal masses	12
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety	12
Re: Hera et al. impact of neoadjuvant therapy on prognosis in renal cell carcinoma with inferior vena cava thrombus	12
Biodynamic prediction of neoadjuvant chemotherapy response: Results from a prospective multicenter study of predictive accuracy among muscle-invasive bladder cancer patients	12
Acetyl-CoA synthetase 2 enhances tumorigenesis and is indicative of a poor prognosis for patients with renal cell carcinoma	11
Contemporary outcomes for robotic radical cystectomy and intracorporeal neobladder urinary diversion	11
Uptake of re-resection in T1 bladder cancer: An interrupted population-based time series analysis among different groups of surgeons	11
Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer	11
Editorial Board	11
State of the Art: The Microbiome in Bladder Cancer	11
PHASE 3 MK-5684-004 STUDY OF CYP11A1 INHIBITOR OPEVESOSTAT VERSUS NEXT-GENERATION HORMONAL AGENT (NHA) SWITCH IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER 1 PRIOR NHA	11
A 25-year perspective on advances in the study of the epidemiology, disparities, and outcomes of urologic cancers	11
Cover 2 - Masthead	11
Bilateral inguinal lymphadenectomy using simultaneous double laparoscopies for penile cancer: A retrospective study	11
Comparative analysis of salvage partial nephrectomy versus radical nephrectomy after the failure of initial partial nephrectomy	11
LARGE LANGUAGE MODEL FOR PROVIDING PATIENT-FOCUSED GUIDANCE FOLLOWING RADICAL PROSTATECTOMY	11
CHANGES IN PROSTATE SPECIFIC ANTIGEN SCREENING FOLLOWING THE 2018 UNITED STATES PREVENTIVE SERVICES TASK FORCE GUIDELINES AND THROUGH THE COVID-19 PANDEMIC	11
PSMA PET/CT-DETECTED MESORECTAL LYMPH NODE METASTASES: TREATMENT OUTCOMES AND CLINICAL IMPLICATIONS	11
SURVIVAL PATTERNS BASED ON SITE-SPECIFIC VISCERAL METASTASIS IN METASTATIC PROSTATE CANCER PATIENTS: ARE OUTCOMES OF VISCERAL METASTASES THE SAME?	11
BLOOD-BASED LIQUID BIOPSY IN DIAGNOSIS, SURVEILLANCE, AND PROGNOSIS OF PATIENTS WITH PRIMARY UPPER TRACT UROTHELIAL CARCINOMA	11
Editorial Board	11
The 5-item frailty index predicts 30-day morbidity and mortality in radical nephrectomy patients: A propensity matched analysis	11
Development of a predictive model for recurrence-free survival in pTa low-grade bladder cancer	11
LOW-GRADE AND HIGH-GRADE INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER RESPOND DIFFERENTLY TO BACILLUS CALMETTE-GUÉRIN AND GEMCITABINE-DOCETAXEL	11
Disparities in access to high-volume centers and in hospital discharge status following radical cystectomy in Florida	11
Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: An Analysis of Real-World Practice Patterns from the CancerLinQ Database	11
Designing lean, efficient clinical trials is an ethical imperative: the fragility index should not be used in the design of randomized clinical trials	11
Assessing the impact of lymphovascular invasion on overall survival in surgically treated renal cell carcinoma patients: A nationwide cohort analysis	10
Leveraging DNA repair deficiency to personalize radiopharmaceutical therapy in prostate cancer	10
Prostate magnetic resonance imaging utilization and its relationship with advanced prostate cancer detection	10
The effect of race on stage at presentation and survival in upper tract urothelial carcinoma	10
Genitourinary toxicity in patients receiving TURP prior to hypofractionated radiotherapy for clinically localized prostate cancer: A scoping review	10
Evaluation of short term surgical outcomes of radical prostatectomy in the decade following the introduction of minimum volume standards in the Netherlands	10
Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy	10
Urothelial carcinoma of the bladder with isolated lymph node metastasis: Natural history and outcomes following surgical resection	10
Unraveling the BMI paradox in different renal cortical tumors: insights from the INMARC registry	10
Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention	10
Pattern and risk factors of local recurrence and intravesical recurrence after segmental ureterectomy for upper tract urothelial carcinoma	10
Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients	10
Masculinity stigma and metastatic prostate cancer: A review with a focus on Latin America	10
Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center	10
Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide	10
HIVEC as an alternative option in non-muscle-invasive bladder cancer: Experiences from a high-volume center	10
Opioid prescription following radical orchiectomy associated with new persistent opioid use	10
Device-related complications during renal cryoablation: insights from the Manufacturer and User Facility Device Experience (MAUDE) database	10
Clinical parameters for the prediction of occult lymph node metastasis in patients with negative PSMA-PET	10
Mutational landscape of non-muscle-invasive bladder cancer	10
Annular-shaped stenosis in the ureter: Caution should be taken	9
The role of autophagy dysregulation in low and high-grade nonmuscle invasive bladder cancer: A survival analysis and clinicopathological association	9

EARLY POSTOPERATIVE CANCER-SPECIFIC DEATH AMONGST PATIENTS WITH HIGH-RISK NON-METASTATIC CLEAR CELL RENAL CELL CARCINOMA: REFINING RISK STRATIFICATION TO OPTIMIZE SELECTION FOR ADJUVANT THERAPY	9
Development of point-of-care tests for urinary bladder cancer – an historic review and view to future prospectives	9
Avoiding “Needless” nephrectomy: What is the role of small renal mass biopsy in 2024?	9
Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment	9
Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma	9
QUANTIFYING THE BENEFIT OF SALVAGE RADIATION THERAPY FOR BIOCHEMICALLY RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY	9
LEVEL OF NODAL METASTASIS IN PATIENTS UNDERGOING RADICAL CYSTECTOMY AND LYMPHADENECTOMY: IS THERE A ROLE OF EXTENDED LYMPHADENECTOMY IN THE POST-S1011 ERA?	9
A PHASE IIB RANDOMIZED PLACEBO-CONTROLLED TRIAL TESTING A LONG-CHAIN OMEGA-3 FATTY ACID MAG-EPA DIETARY SUPPLEMENT ON PROSTATE CANCER AND GUT MICROBIOME	9
Association of heavy metals and trace elements in renal cell carcinoma: A case-controlled study	9
INCIDENCE AND PATHOLOGIC OUTCOMES OF CYSTECTOMY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON–MUSCLE-INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU FOLLOWING TREATMENT WITH NADOFARAGENE F	9
THE PROGNOSTIC ROLE OF THE NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER PATIENTS TREATED WITH INTRAVESICAL GEMCITABINE AND DOCETAXEL	9
Clinically significant prostate cancer detection rate in biopsy-naïve patients with mpMRI and microultrasound topographically discordant lesions: A single-center retrospective analysis	9
Thermal ablation for local tumor recurrence after previous partial nephrectomy: Perioperative and oncological outcomes	9
Intra-arterial chemotherapy plus BCG, a promising combination adjuvant treatment for high-risk NMIBC	9
Diagnostic yield of upper tract imaging performed for hematuria screening: Results from a national, privately-insured cohort	9
THE PROGNOSTIC SIGNIFICANCE OF CIRCULATING TUMOR DNA IN PATIENTS WITH POSITIVE LYMPH NODE DISEASE AFTER ROBOTIC-ASSISTED RADICAL CYSTECTOMY	9
Intra-arterial chemotherapy combined with BCG immunotherapy is more effective than intra-arterial chemotherapy plus intravesical chemotherapy or standard BCG immunotherapy in preventing the recurrence	9
HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER WITH VARIANT HISTOLOGY OR OTHER SUBTYPES NOT A PREDICTOR FOR PROGRESSION IN BCG-TREATED PATIENTS	9
THE NONCANONICAL WNT PATHWAY (FYN/STAT3) ACTIVATED BY YY1 PROMOTES THE NEUROENDOCRINE DIFFERENTIATION OF PROSTATE CANCER CELLS.	9
INTRAVESICAL AUTOLOGOUS TIL THERAPY IN BCG-EXPOSED NMIBC: A REPORT OF EARLY SAFETY AND EFFICACY FINDINGS	9
A machine learning approach to predict progression on active surveillance for prostate cancer	9
“I was in a very deep, dark place... I wasn't prepared for that”: A qualitative assessment of the emotional well-being needs of patients undergoing cystectomy	9
Steroidogenesis in castration-resistant prostate cancer	9
Preoperative risk calculator for the probability of completing nephron sparing for kidney cancer	9
Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma	9
MAPPING PATTERNS OF RECURRENCE AFTER SALVAGE LYMPH NODE DISSECTION IN PATIENTS WITH METASTATIC PROSTATE CANCER	9
2023 Star Reviewers for Urologic Oncology	9
THE ASSOCIATION BETWEEN HEALTH LITERACY AND ALL-CAUSE MORTALITY IN UROLOGIC CANCER PATIENTS	9
COMPARING ACTIVE SURVEILLANCE AND WATCHFUL WAITING AND RADICAL TREATMENT USING MACHINE LEARNING MODELS AMONG PROSTATE CANCER PATIENTS	8
GRADE AND VOLUME PROGRESSION AND ITS ASSOCIATION WITH THE DECIPHER GENOMIC CLASSIFIER USING PATIENTS ENROLLED IN A PROSPECTIVE ACTIVE SURVEILLANCE PROTOCOL	8
STIMULATED RAMAN HISTOLOGY AND ARTIFICIAL INTELLIGENCE ALLOWS FOR PREDICTION OF PROSTATE CANCER EXTRAPROSTATIC EXTENSION AND POSITIVE SURGICAL MARGIN DURING RADICAL PROSTECTOMY	8
EARLY ONCOLOGIC OUTCOME AND PSA KINETICS FOLLOWING IRREVERSIBLE ELECTROPORATION IN MEN WITH PROSTATE CANCER	8
Risk of adverse pathology at prostatectomy in the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate cancer patients	8
Cause-specific mortality among patients with renal cell carcinoma in the United States from 2000 to 2018	8
Characterization and management of NMIBC recurrences after TMT: a matched cohort analysis	8
The CAG-triplet in the androgen receptor gene and single-nucleotide polymorphisms in androgen pathway genes in patients with concomitant bladder and prostate cancer	8
Epigenetics regulation of prostate cancer: Biomarker and therapeutic potential	8
SEQUENTIAL ENDOLUMINAL GEMCITABINE AND CABAZITAXEL WITH SYSTEMIC PEMBROLIZUMAB FOR RECURRENT NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE UPPER AND LOWER URINARY TRACTS	8
The relationship between BCG immunotherapy and oxidative stress parameters in patients with nonmuscle invasive bladder cancer	8
Prognostic significance of pathologic response to neoadjuvant chemotherapy in muscle-invasive urothelial carcinoma of the bladder with histologic subtype	8
Investigating the pattern of prostate specific antigen screening among E-cigarette smokers within the behavioral risk factor surveillance system	8
Deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma: A systematic review and patient-level meta-analysis	8
CARCINOMA IN SITU AND URINARY CYTOLOGY AS AN INDICATOR OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER TREATED WITH BCG	8
Michael Droller: An appreciation, for his Festschrift 2024	8
PIVOT-006: A PHASE 3, RANDOMIZED STUDY OF ADJUVANT INTRAVESICAL CRETOSTIMOGENE GRENADENOREPVEC VERSUS SURVEILLANCE FOR THE TREATMENT OF INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER	8
DEVELOPMENT AND EXTERNAL VALIDATION OF A LOCAL PELVIC RECURRENCE RISK SCORE AFTER RADICAL CYSTECTOMY: IDENTIFYING THE IDEAL CANDIDATE FOR ADJUVANT RADIATION CLINICAL TRIALS	8
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer	8
Second line salvage systemic therapy for advanced penile cancer	8
Cover 2 - Masthead	8
Update on organ preserving surgical strategies for penile cancer	8
Cover 2 - Masthead	8
25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology	8
Liquid biopsy testing in urological cancers: Focus on urine	8
Predictive factors for recurrence and outcomes in T1a renal cell carcinoma: Analysis of the INMARC (International Marker Consortium for Renal Cancer) database	8
Current controversies on the role of lymphadenectomy for testicular cancer for the journal: Urologic Oncology: Seminars and Original Investigations for the special seminars section on the role of lymp	8
Editorial Board	8
ONCOLOGIC OUTCOMES OF BLADDER-SPARING MANAGEMENT FOR HIGH-GRADE NON-INVASIVE UROTHELIAL CARCINOMA OF THE PROSTATIC URETHRA	8
RISK FACTORS FOR PROGRESSION IN PATIENTS WITH POST-BCG RECURRENT NMIBC	8
THE DISPARITY OF LYMPH NODE DISSECTION IN T2+N0M0 STAGE PENILE SQUAMOUS CELL CARCINOMA PATIENTS	8
A mindful approach to complications: Brief review of the literature and practical guide for the surgeon	8
Non-muscle-invasive bladder cancer: An overview of potential new treatment options	8
Contemporary morbidity and mortality of open versus robotic cystectomy for bladder cancer: An analysis of the National Surgical Quality Improvement Program (NSQIP) procedure targeted cystectomy databa	8
Introduction to the 25th anniversary issue	8
Outcomes with brachytherapy based dose escalation for gleason 8 versus 9-10 prostate cancer: An NCDB analysis	8
Re: Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer. Yanagisawa T, Sato S, Hayashida Y, Okada Y, Fukuokaya W, Iwatani K, et al. J Urol Oncol. 2023;41(12):484.e7-484.e15	8
Rates of volume reduction after selective arterial embolization for renal angiomyolipoma	8
Artificial intelligence in prostate cancer: Definitions, current research, and future directions	8
The efficacy of adjuvant mitotane therapy and radiotherapy following adrenalectomy in patients with adrenocortical carcinoma: A systematic review and meta-analysis	8
Cover 2 - Masthead	7
SUBOPTIMAL REPORTING OF ADVERSE EVENTS IN RCTs SUPPORTING BLADDER CANCER CLINICAL PRACTICE GUIDELINES	7
GENE EXPRESSION DIFFERENCES AND PATHWAY ACTIVATION BY RACE IN ERG+ PROSTATE CANCERS: IMPLICATIONS FOR EQUITABLE CANCER CARE	7
CYTOREDUCTIVE NEPHRECTOMY IS ASSOCIATED WITH IMPROVED SURVIVAL FOR SARCOMATOID METASTATIC RENAL CELL CARCINOMA PATIENTS TREATED BEFORE OR AFTER SURGERY WITH IMMUNE CHECKPOINT INHIBITORS	7
The additive value of mpMRI on prostate cancer detection: Comparison between patients with and without a suspicious digital rectal examination (DRE)	7
Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions	7
Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab	7
CONCOMITANT SECOND-GENERATION HORMONE THERAPY WITH RADIUM-223 IN THE THIRD-LINE SETTING: DOES IT IMPROVE OVERALL SURVIVAL?	7
RADIATION THERAPY AND IRREVERSIBLE ELECTROPORATION (RTIRE) FOR INTERMEDIATE RISK PROSTATE CANCER: A PHASE II ONGOING TRIAL	7
Editorial Board	7
Does neoadjuvant chemotherapy diminish the sex disparity in bladder cancer survival after radical cystectomy?	7
EVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES	7
Table of Contents	7
Clinician interest in clinical decision support for PSA-based prostate cancer screening	7
Global trends and regional variations in PCa burden: A focus on China's rapid growth	7
Can Retroperitoneal Lymph Node Dissection (RPLND) be feasibly performed to prolong survival in Renal Cell Carcinoma (RCC) with limited lymph node involvement? An Analysis of Recurrence Patterns	7
HOME INSTILLATION OF UGN-102 FOR PRIMARY CHEMOABLATION OF RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER: A SINGLE-ARM, OPEN-LABEL, PHASE 3B TRIAL	7
Festschrift honoring Michael Droller	7
DEVELOPMENT AND TESTING OF A CUSTOM NANOSTRING RNA CODESET FOR MUSCLE-INVASIVE BLADDER CANCER UTILIZING TCGA SUBTYPING (SWOG S1011)	7
Cover 2 - Masthead	7
CONCORDANCE BETWEEN CLINICAL AND PATHOLOGIC STAGING OF T2A-B AND T3A RENAL CELL CARCINOMA: IMPLICATIONS FOR FUTURE PERIOPERATIVE CLINICAL TRIALS	7
Corrigendum to < Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer>, urologic oncology: Seminars and original inve	7
Surgical templates for inguinal lymph node dissection in cN0 penile cancer: A comparative study	7
Metformin intake and risk of metabolic acidosis after radical cystectomy with urinary diversion: A comparative study using data from the TriNetX research network	7
Oncogenic MicroRNAs: Key players in human prostate cancer pathogenesis, a narrative review	7
UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancer	7
ROLE OF TUMOR MICROENVIRONMENT DERIVED NRG1 IN ANDROGEN RESISTANCE: IMPLICATIONS FOR A NOVEL PROSTATE CANCER TREATMENT STRATEGY	7